# Influence of Myeloperoxidase Levels on Periodontal Disease: An Applied Clinical Study
## 3 Results
Moreover, the p-for trend analysis test evidenced that MPO in serum increased gradually in subjects with periodontitis, CVD, and with periodontitis plus CVD (\(p\)-trend \(<\)0.001) (Figure 3). No statistically significant associations were found in MPO levels between serum and saliva (rs = 0.213, \(p=0.098\)). Moreover, in all enrolled patients presented a positive correlation between serum/salivary MPO and hs-CRP levels (rs = 0.341, \(p<0.001\))/(rs = 0.609, \(p<0.001\)) (Figure 3). \begin{table}
\begin{tabular}{c c c c c} \hline \hline \multicolumn{1}{c}{**Controls (N = 31)**} & \multicolumn{2}{c}{**Periodontitis (N = 31)**} & \multicolumn{2}{c}{**CVD**} \\  & & & **(N = 31)** & \\ \hline N\({}^{\circ}\) of teeth & 26 (21; 27) & 20 (15; 21)\({}^{**}\) & 23 (19; 26) \({}^{**,86}\) & 18 (12; 20) \({}^{**,86}\) \\ \hline CAL (mm) & 1 (0.9; 1.3) & 3.6 (3.1; 4.2) \({}^{**}\) & 2 (1.8; 2.4) \({}^{**,86}\) & 3.4 (3; 4.1) \({}^{**,82}\) \\ \hline CAL 4-5 mm (\% sites) & - & 38.7 (35.4; 42.9) \({}^{**}\) & - & 40.6 (35.5; 46.1) \({}^{**,82}\) \\ \hline CAL \(\geq\)6 mm (\% sites) & - & 18.7 (19.6; 22.3) \({}^{**}\) & - & 17.4 (15.8; 22.7) \({}^{**}\) \\ \hline PD (mm) & 1.5 (1.3; 1.9) & 4.4 (3.7; 4.6) \({}^{**}\) & 2.1 (1.8; 2.4) \({}^{**,86}\) & 3.9 (3.7; 4.4) \({}^{**,82}\) \\ \hline PD 4–5 mm (\% sites) & - & 40.9 (38.6; 45.7) \({}^{**}\) & - & 44.1 (42.7; 55.3) \({}^{**,82}\) \\ \hline PD \(\geq\)6 mm (\% sites) & - & 23.1 (19.8; 25.2) \({}^{**}\) & - & 22.7 (20.3; 26.5) \({}^{**,88,87}\) \\ \hline BOP (\%) & 7.9 (6.5; 8.3) & 41.2 (34.3; 46.5) \({}^{**}\) & 8.1 (6.4; 8.9) \({}^{**,86}\) & 42.3 (41.5; 50.1) \({}^{**,86,88}\) \\ \hline Rx alveolar bone loss (mm) & 0.2 (0.1; 0.5) & 2.9 (2.5; 3.4) \({}^{**}\) & 0.3 (0.2; 0.9) \({}^{**,86}\) & 3.3 (2.1; 4.6) \({}^{**,82}\) \\ \hline PI (\%) & 6.5 (4.7; 9.3) & 35.4 (31.7; 37.9) \({}^{**}\) & 11.7 (9.1; 12.8) \({}^{**,88}\) & 32.4 (27.2; 36.1) \({}^{**,82}\) \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Periodontal characteristics of enrolled patients. Data are represented as median (25 th; 75 th percentile). CAL, clinical attachment level; PD, probing pocket depth; BOP, bleeding on probing; PI, plaque index. \({}^{**}\)\(p<0.001\) significant differences vs. control subjects. \({}^{88}\)\(p<0.001\) significant differences vs. periodontitis patients. \({}^{**}\)\(p<0.001\) significant differences vs. CHD patients. Figure 2: Median values (25%; 75% percentiles) of coronary heart disease (MPO) in saliva and serum. \({}^{*}\)\(p<0.05\), \({}^{**}\)\(p<0.01\) and \({}^{***}\)\(p<0.001\) significant differences vs. control subjects (derived by the Kruskal–Wallis test). SSSS \(p<0.01\) significant differences vs. periodontitis patients. \(p<0.001\). The univariate regression analysis evidenced that there was a significant direct impact of hs-CRP on serum and salivary MPO (both \(p<0.001\)). Furthermore, the adjusted multivariate linear regression analysis evidenced that hs-CRP variable was the only significant predictor for serum MPO (\(p<0.001\)). Moreover, hs-CRP (\(p<0.001\)) and total cholesterol (\(p=0.035\)) were the statistically significant predictor variables for salivary MPO (Table 3).